By Dr. Juan Jose Orduna MBBS., MBA. – Stemwell – Regenerative Medicine
Every year on May 10th, World Lupus Day raises awareness of lupus, a complex autoimmune condition affecting millions of people worldwide.
Lupus can impact the skin, joints, kidneys, brain, and other organs. It is often unpredictable, with symptoms that vary over time, making diagnosis and long-term management challenging.
At the same time, medical research is advancing rapidly. In particular, regenerative medicine is opening new possibilities for improving how we understand and potentially treat autoimmune diseases like lupus.
What is Lupus?
Lupus (systemic lupus erythematosus, or SLE) is a condition where the immune system becomes overactive and mistakenly attacks the body’s own tissues.
Instead of protecting the body, the immune system triggers inflammation that can affect multiple organs.
Common symptoms include:
- Fatigue that does not improve with rest
- Joint pain and swelling
- Skin rashes, often on the face
- Sensitivity to sunlight
- In more severe cases, kidney or organ involvement
Lupus often follows a pattern of flares (worsening symptoms) and remission (improvement).
Why Awareness Matters
Lupus is sometimes difficult to diagnose because its symptoms overlap with other conditions. This can lead to delays in treatment.
Greater awareness helps by:
- Supporting earlier diagnosis
- Reducing misunderstanding and stigma
- Improving emotional and social support
- Encouraging research and innovation
Current Treatments: Effective but Limited in Scope
Standard treatments such as corticosteroids, immunosuppressants, and biologics can help control inflammation and reduce flares.
However, they may not work for all patients and can have side effects over time. This has led to growing interest in regenerative medicine that go beyond symptom control and aim to restore immune balance.
Regenerative Medicine: A New Frontier in Lupus Care
Regenerative medicine is being explored as a potential approach to restore immune balance and modulate dysfunctional immune networks. At Stemwell, research interest is focused on evidence-based regenerative and immune-modulating strategies that support the body’s intrinsic regulatory systems.
These approaches do not replace conventional therapies but aim to complement them through immune system rebalancing. Several innovative approaches are currently being studied for their potential role in lupus care:
- Mesenchymal Stem Cell (MSC) Therapy
MSC therapy is one of the most studied regenerative approaches in autoimmune disease.
A 2025 meta-analysis of 42 randomized controlled trials involving 2,183 patients showed that MSC therapy significantly improved disease activity without increasing adverse events (1).
These cells may help by:
- Reducing abnormal immune activity
- Decreasing inflammation
- Supporting immune regulation (3–6)
In simple terms, MSCs may help rebalance an overactive immune system rather than suppressing it broadly.
- CAR T-Cell Therapy (Advanced Immunotherapy)
CAR T-cell therapy, originally developed for cancer, is now being explored in severe autoimmune diseases such as lupus. Early studies report that some patients achieved deep and sustained remission, including drug-free periods in certain cases (7,8).
More recent studies using dual-target CAR T cells have shown remission rates of up to 80% in treatment-resistant patients (10,11).
This therapy works by eliminating immune cells responsible for producing harmful autoantibodies, allowing the immune system to reset (13,14).
- Hematopoietic Stem Cell Transplantation (AHSCT)
AHSCT aims to reboot the immune system.
Studies suggest that 50–70% of carefully selected patients may achieve long-term remission (17,18).
Long-term follow-up data supports sustained disease control in many cases, although this is an intensive procedure requiring careful patient selection (16).
- Regulatory T Cell (Treg) Therapies
Treg-based therapies aim to restore immune balance rather than suppress immunity.
Low-dose IL-2 therapy has shown that:
- Over 90% of patients experience expansion of regulatory T cells
- Many patients show improvement in disease activity (20,21)
Emerging adoptive and engineered Treg therapies are also showing early promise (19,22,23).
Genetics and Precision Immunology in Lupus
Lupus is a complex condition influenced by a combination of genetics, the immune system, and environmental triggers. This is why it can vary greatly from person to person.
Rather than being caused by a single gene, lupus develops through multiple genetic factors that affect immune regulation. Key mechanisms include variations in immune-related genes (such as HLA), changes in the complement system, and overactivation of inflammatory pathways like type I interferon signaling.
However, genetics alone are not enough to cause lupus. External factors such as sunlight (UV exposure), infections, and hormonal influences like estrogen can also play an important role in triggering or worsening the disease.
Together, these factors help explain why lupus can appear suddenly or fluctuate over time.
Advances in genomic technology are now helping researchers better understand these individual differences. Genetic analysis can provide deeper insight into immune function and disease susceptibility, supporting a more personalized approach to care.
Safety and Outlook
Across regenerative medicine approaches, safety data is encouraging:
- MSC therapy shows no increase in adverse events compared to standard care (1,24)
- CAR T-cell therapy is generally manageable with appropriate monitoring (7,8,10)
- IL-2 and Treg therapies are typically well tolerated (20)
- AHSCT remains more intensive but continues to improve in safety (16–18)
Final Message
Living with lupus can be challenging, but today there is more hope than ever. Advances in regenerative medicine are opening new possibilities not just to manage symptoms, but to improve quality of life in a deeper, more lasting way
At Stemwell, our commitment remains:
- Patient-centered care
- Scientific rigor
- Safe and responsible regenerative medicine
World Lupus Day is not only about raising awareness, it is also about progress, innovation, and hope for the future.
References
- Zeng L, Liu C, Wu Y, et al. Stem Cell Res Ther. 2025.
- Farge D, Biard L, Weil B, et al. Lancet Rheumatol. 2025.
- Yang Q, Liu Y, Chen G, et al. Stem Cells Int. 2021.
- Yu H, Li Q, Zhu H, et al. Int Immunopharmacol. 2024.
- Li A, Guo F, Pan Q, et al. Front Immunol. 2021.
- Li J, Luo M, Li B, et al. Front Immunol. 2022.
- Mackensen A, Müller F, Mougiakakos D, et al. Nat Med. 2022.
- Müller F, Taubmann J, Bucci L, et al. N Engl J Med. 2024.
- Mougiakakos D, Krönke G, Völkl S, et al. N Engl J Med. 2021.
- Feng J, Huo D, Hong R, et al. Nat Med. 2025.
- Wang W, He S, Zhang W, et al. Ann Rheum Dis. 2024.
- Wang Q, Xiao ZX, Zheng X, et al. N Engl J Med. 2025.
- Schett G, Mackensen A, Mougiakakos D. Lancet. 2023.
- Avouac J, Barzel A, Caiati D, et al. Nat Rev Drug Discov. 2026.
- Durcan L, O’Dwyer T, Petri M. Lancet. 2019.
- Goklemez S, Hasni S, Hakim FT, et al. Rheumatology. 2022.
- Illei GG, Cervera R, Burt RK, et al. Ann Rheum Dis. 2011.
- Murphy G, Lisnevskaia L, Isenberg D. Lancet. 2013.
- Doglio M, Ugolini A, Bercher-Brayer C, et al. Nat Commun. 2024.
- Humrich JY, von Spee-Mayer C, Siegert E, et al. Lancet Rheumatol. 2019.
- von Spee-Mayer C, Siegert E, Abdirama D, et al. Ann Rheum Dis. 2016.
- Dall’Era M, Pauli ML, Remedios K, et al. Arthritis Rheumatol. 2019.
- Lyu MA, Tang X, Khoury JD, et al. Front Immunol. 2023.
- Zhou T, Li HY, Liao C, Lin W, Lin S. Stem Cells Int. 2020.
Ready to learn more about stem cell therapy?
At Stemwell, our team of doctors are highly skilled in successfully supporting thousands of people with a range of stem cell treatments. If you would like to learn more about stem cell therapy you can contact us with any questions, or apply today to check your eligibility.
